Zacks: Brokerages Expect Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Will Post Earnings of -$0.73 Per Share
Brokerages expect Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) to report ($0.73) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Tonix Pharmaceuticals Holding Corp.’s earnings, with the highest EPS estimate coming in at ($0.69) and the lowest estimate coming in at ($0.76). Tonix Pharmaceuticals Holding Corp. posted earnings per share of ($5.00) in the same quarter last year, which indicates a positive year-over-year growth rate of 85.4%. The company is expected to issue its next earnings report on Friday, August 4th.
On average, analysts expect that Tonix Pharmaceuticals Holding Corp. will report full year earnings of ($3.15) per share for the current fiscal year, with EPS estimates ranging from ($3.35) to ($2.96). For the next fiscal year, analysts forecast that the business will post earnings of ($1.87) per share, with EPS estimates ranging from ($2.14) to ($1.60). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Tonix Pharmaceuticals Holding Corp..
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last released its quarterly earnings results on Monday, May 15th. The company reported ($1.27) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.09.
Separately, Aegis began coverage on Tonix Pharmaceuticals Holding Corp. in a report on Monday, June 26th. They set a “buy” rating and a $10.00 price objective for the company.
TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/07/18/zacks-brokerages-expect-tonix-pharmaceuticals-holding-corp-nasdaqtnxp-will-post-earnings-of-0-73-per-share.html.
Tonix Pharmaceuticals Holding Corp. (TNXP) opened at 4.34 on Tuesday. The stock’s 50 day moving average is $4.23 and its 200 day moving average is $2.48. The company’s market cap is $32.49 million. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $3.30 and a 52-week high of $28.00.
In other Tonix Pharmaceuticals Holding Corp. news, Director Ernest Mario sold 6,105 shares of Tonix Pharmaceuticals Holding Corp. stock in a transaction on Friday, June 30th. The stock was sold at an average price of $4.28, for a total transaction of $26,129.40. Following the completion of the transaction, the director now directly owns 63,073 shares of the company’s stock, valued at $269,952.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Seth Lederman acquired 20,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The shares were bought at an average cost of $4.22 per share, with a total value of $84,400.00. Following the completion of the acquisition, the chief executive officer now owns 7,912 shares of the company’s stock, valued at approximately $33,388.64. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 30,000 shares of company stock valued at $128,050. Company insiders own 4.00% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC bought a new position in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter worth about $119,000. Dialectic Capital Management LP bought a new position in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter worth about $187,000. Finally, Renaissance Technologies LLC boosted its position in shares of Tonix Pharmaceuticals Holding Corp. by 108.4% in the fourth quarter. Renaissance Technologies LLC now owns 774,603 shares of the company’s stock worth $364,000 after buying an additional 402,898 shares during the last quarter. 17.53% of the stock is owned by institutional investors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related stocks with our FREE daily email newsletter.